Alexandria Venture Investments, LLC - 26 Oct 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
10%+ Owner
Signature
By: ALEXANDRIA REAL ESTATE EQUITIES, INC., a Maryland corporation, managing member By: /s/ Dean A. Shigenaga Chief Financial Officer
Issuer symbol
XLO
Transactions as of
26 Oct 2021
Net transactions value
$0
Form type
4
Filing time
26 Oct 2021, 16:51:39 UTC
Previous filing
21 Oct 2021
Next filing
06 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLO Common stock Conversion of derivative security +166,423 166,423 26 Oct 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Series B convertible preferred stock Conversion of derivative security -1,581,026 -100% 0 26 Oct 2021 Common stock 166,423 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Alexandria Venture Investments, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date.
F2 Not applicable.